70
Participants
Start Date
May 23, 2016
Primary Completion Date
July 7, 2022
Study Completion Date
August 8, 2026
Biopsy Procedure
Undergo biopsy of tumor
Biospecimen Collection
Undergo blood sample collection
Cediranib Maleate
Given PO
Computed Tomography
Undergo CT scan
Echocardiography Test
Undergo echocardiogram
Magnetic Resonance Imaging
Undergo MRI scan
Multigated Acquisition Scan
Undergo MUGA
Olaparib
Given PO
Questionnaire Administration
Ancillary studies
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
National Institutes of Health Clinical Center, Bethesda
NCI - Center for Cancer Research, Bethesda
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Duke University Medical Center, Durham
Moffitt Cancer Center, Tampa
Ohio State University Comprehensive Cancer Center, Columbus
Mayo Clinic in Rochester, Rochester
Mayo Clinic Hospital in Arizona, Phoenix
Mayo Clinic in Arizona, Scottsdale
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
Keck Medical Center of USC Pasadena, Pasadena
Mayo Clinic in Florida, Jacksonville
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH